drugset / Trial / NCT04025216
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).
Timeline
- Start
- 2019-10-10
- Primary completion
- 2022-12-02
- Completion
- 2022-12-02
Outcome
Outcome not reported
Stopped: “The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-TnMUC1 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |